At a glance
- Originator Kaken Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Sep 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 04 Oct 1996 Preclinical development for Cancer in Japan (Unknown route)